Yi, Yin, et al. Carbohydrate Polymers 334 (2024): 122039.
Sucrose acetate isobutyrate (SAIB) has been integrated into a novel hybrid hydrogel formulation to enhance the controlled, on-demand drug delivery for bone defect regeneration. In this study, SAIB was used in combination with sodium alginate and electrospun microspheres to create a hydrogel system responsive to ultrasound stimulation. The inclusion of SAIB played a critical role in preventing burst release, effectively modulating the drug release rate within the hydrogel matrix.
When exposed to ultrasound, the ionic bonds within the sodium alginate network were broken, triggering drug release. However, the presence of SAIB significantly reduced the rapid initial release, ensuring a more controlled and sustained delivery. This dual-responsive system, combining SAIB's stabilizing properties with ultrasound-triggered release, exhibited excellent injectability, mechanical strength, and biodegradability.
In vivo studies demonstrated that the hydrogel system promoted osteogenesis, activating the PI3K-AKT signaling pathway, which accelerated bone regeneration. This approach holds great promise for treating bone defects, offering a precision drug delivery strategy that could be tailored for optimal therapeutic outcomes. While further studies on in vivo drug concentrations are needed, SAIB's role in enhancing drug release kinetics makes it a valuable component for advancing regenerative medicine and bone healing therapies.
Elshafeey, Ahmed Hassen, et al. Journal of Drug Delivery Science and Technology 58 (2020): 101806.
Sucrose acetate isobutyrate (SAIB) has been effectively utilized as a surfactant in the development of nanovesicles aimed at improving the bioavailability of poorly soluble drugs, such as Ticagrelor (TR). SAIB-based nanovesicles (SBN) were formulated with Poloxamer 407 to enhance the solubility and absorption of TR, a BCS Class IV drug. The optimized nanovesicular formulation, characterized by a 5.52:1 surfactant:drug ratio and 0.1:1 SAIB:Poloxamer 407 ratio, demonstrated significant improvements in drug dissolution and absorption.
The prepared SBN dispersions, with a particle size of less than 200 nm, showed enhanced drug release compared to both the pure drug and the marketed product. Pharmacokinetic studies in rabbits confirmed a 150% increase in relative bioavailability, with the area under the plasma concentration-time curve (AUC) for the nanostructured tablets reaching 4163.52 ng h/mL, compared to 2824.16 ng h/mL for the marketed product. The lyophilized nanovesicles further stabilized the formulation, enhancing its physical stability for oral administration.
This research underscores the potential of SAIB as a surfactant in nanovesicular systems, offering a promising strategy for enhancing the solubility, permeability, and bioavailability of poorly absorbed drugs.
Al-Shoubki, Adam A., et al. "Potential application of sucrose acetate isobutyrate, and glyceryl monooleate for nanonization and bioavailability enhancement of rivaroxaban tablets." Pharmaceutical Science Advances 2 (2024): 100015.
Sucrose acetate isobutyrate (SAIB) has shown significant promise as a surfactant in the formulation of nanovesicular systems aimed at enhancing the bioavailability of poorly soluble drugs. In this study, SAIB was combined with Glyceryl monooleate (GMO) to prepare cubosomes and SAIB-based nanodispersions for Rivaroxaban (RXB), a BCS Class II drug. The formulations were optimized by varying the polymer-to-drug ratios and maintaining a fixed polymer-to-Poloxamer 407 ratio, with the resulting dispersions exhibiting optimal particle size, entrapment efficiency, and stability.
Both cubosomal and SAIB-based nanodispersions significantly enhanced the dissolution and bioavailability of RXB compared to the marketed product. The lyophilized formulations showed improved drug release profiles, and pharmacokinetic studies in animals confirmed better bioavailability, likely due to improved solubility and absorption. The study also emphasized the critical role of SAIB and GMO concentrations in controlling the size and stability of the nanoparticles, with the optimal formulations leading to enhanced drug delivery efficiency.
This research highlights SAIB's potential as an effective surfactant for enhancing the solubility, bioavailability, and therapeutic efficacy of RXB in nanoformulations. The findings suggest that SAIB-based formulations could reduce the required dosage for the desired therapeutic effect, offering a promising approach for improving drug delivery systems in the pharmaceutical industry.
What is the CAS number for Sucrose acetate isobutyrate?
The CAS number for Sucrose acetate isobutyrate is 126-13-6.
What are some synonyms for Sucrose acetate isobutyrate?
Some synonyms for Sucrose acetate isobutyrate include SAIB and Sucrose di(acetate) hexaisobutyrate.
What is the molecular weight of Sucrose acetate isobutyrate?
The molecular weight of Sucrose acetate isobutyrate is 846.91.
What is the molecular formula of Sucrose acetate isobutyrate?
The molecular formula of Sucrose acetate isobutyrate is C40H62O19.
What is the melting point of Sucrose acetate isobutyrate?
The melting point of Sucrose acetate isobutyrate is -83°C.
What is the flash point of Sucrose acetate isobutyrate?
The flash point of Sucrose acetate isobutyrate is 296.6°C.
What is the density of Sucrose acetate isobutyrate?
The density of Sucrose acetate isobutyrate is 1.22 g/cm³.
What is the physical state of Sucrose acetate isobutyrate?
The physical state of Sucrose acetate isobutyrate is solid.
What are the typical applications of Sucrose acetate isobutyrate?
The typical applications of Sucrose acetate isobutyrate include use as an emulsifying agent and dispersing agent, as well as use as a plasticizer.
What is the percentage of actives in Sucrose acetate isobutyrate?
The percentage of actives in Sucrose acetate isobutyrate is 95%.
CONNECT WITH US
Interested in our Services & Products ?
Need detailed information?
Terms & Conditions
Privacy Policy | Cookie Policy | Copyright © 2025 Alfa Chemistry. All rights reserved.
PAGE TOP
